(IDYA) Ideaya Biosciences - Ratings and Ratios

Ideaya Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company focused on developing targeted therapeutics for genetically defined patient populations. The company leverages molecular diagnostics to identify specific patient groups likely to benefit from its treatments. Its pipeline includes IDE196, a protein kinase C inhibitor in Phase 2/3 trials for cancers with GNAQ or GNA11 mutations; IDE397, a methionine adenosyltransferase 2a inhibitor in Phase 2 trials for solid tumors with MTAP deletions, including non-small cell lung cancer (NSCLC) and urothelial cancer; IDE849, a DLL3 antibody drug conjugate in Phase 1 for SCLC and neuroendocrine tumors; and IDE275, a Werner Helicase inhibitor in Phase 1 for high microsatellite instability tumors. Additionally, the company is advancing IDE161, a PARP glycohydrolase inhibitor, and IDE705, a Poly Theta Helicase inhibitor, both in early-stage trials for HRD-associated cancers. Preclinical programs include IDE892, a PRMT5 inhibitor, and bispecific ADC candidates like IDE034. The company also utilizes advanced drug discovery platforms, including CRISPR libraries and machine-learning engines, to identify synthetic lethality targets and optimize its pipeline.

Ideaya has established strategic partnerships with major pharmaceutical companies, including GlaxoSmithKline, Pfizer, Gilead Sciences, Merck, and Biocytogen, as well as academic institutions like Cancer Research UK and the University of Manchester. These collaborations enhance its research and development capabilities, accelerating the progression of its precision medicine pipeline. Founded in 2015 and headquartered in South San Francisco, California, Ideaya Biosciences is positioned as a leader in the field of targeted oncology therapeutics, with a strong focus on genetically defined cancers and innovative drug discovery technologies.

3-Month Forecast - Technical Outlook: With the stock trading below its SMA200 (~27.62) and above its SMA50 (~18.25), the near-term trend may face resistance at the SMA200 level. Support is likely at SMA50 (~18.25), with ATR (~1.23) indicating moderate volatility. - Fundamental Outlook: The companys high P/S ratio (~213.59) reflects investor confidence in its pipeline potential, though the lack of profitability (RoE: -25.91) underscores the developmental nature of the business. Market cap (~$1.5B) and forward P/E (~4.65) suggest expectations for future growth.